lorlatinib
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
Pfizer Reports Mixed Revenues for Oncology Products in Q4, Looks to Advancing Pipeline in 2024
Premium
With the completion of its acquisition of Seagen in December, the firm is aiming to become a leader in precision oncology.
Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.